References
- Brain Trauma Foundation, American Association of Neurological Surgeons, Congress of Neurological Surgeons. Guidelines for the management of severe traumatic brain injury. Journal of Neurotrauma 2007;24(Suppl 1):S1–106
- Chang BS, Lowenstein DH. Practice parameter: Antiepileptic drug prophylaxis in severe traumatic brain injury. Neurology 2003;60:10–16
- Jones KE, Puccio AM, Harshman KJ, Falcione B, Benedict N, Jankowitz BT, Stippler M, Fischer M, Sauber-Schatz EK, Fabio A, et al. Levetiracetam versus phenytoin for seizure prophylaxis in severe traumatic brain injury. Neurosurgical Focus 2008;25:E3
- Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, randomized, single-blind comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocritical Care 2010;12:165–172
- Inaba K, Menaker J, Branco BC, Gooch J, Okoye OT, Herrold J, Scalea TM, DuBose J, Demetriades D. A prospective multicenter comparison of levetiracetam versus phenytoin for early posttraumatic seizure prophylaxis. Journal of Trauma & Acute Care Surgery 2013;74:766–773
- DeWolfe JL, Szaflarski JP. Levetiracetam use in the critical care setting. Frontiers in Neurology 2013;4:1–6
- Kruer RM, Harris LH, Goodwin H, Kornbluth J, Thomas KP, Slater LA, Haut ER. Changing trends in the use of seizure prophylaxis after traumatic brain injury: A shift from phenytoin to levetiracetam. Journal of Critical Care 2013;28:e9–13
- Sekhon MS, McLean N, Henderson WR, Chittock DR, Griesdale DE. Association of hemoglobin concentration and mortality in critically ill patients with severe traumatic brain injury. Critical Care 2012;16:R128
- Rovlias A, Kotsou S. The blood leukocyte count and its prognostic significance in severe head injury. Surgical Neurology 2001;55:190–196
- Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecg C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics 1981;30:239–245
- Kane-Gill SL, Kirisci L, Pathak DS. Are the Naranjo Criteria reliable and valid for determination of adverse drug reactions in the intensive care unit? Annals of Pharmacotherapy 2005;39:1823–1827
- Keppra® [package insert]. Smyrna, GA: UCB Inc.; 2012
- Gallerani M, Mari E, Boari B, Carletti R, Marra A, Cavallo M. Pancytopenia associated with levetiracetam treatment. Clinical Drug Investigation 2009;29:747–751
- Elouni B, Ben Salem C, Biour M. Levetiracetam-induced pancytopenia. Annals of Pharmacotherapy 2009;43:985
- Sahaya K, Goyal MK, Sarwal A, Singh NN. Levetiracetam-induced thrombocytopenia among inpatients: A retrospective study. Epilepsia 2010;51:2492–2495
- Oghlakian R, Nock C, Koubeissi M. A case of levetiracetam-induced thrombocytopenia. Epileptic Disorders 2010;12:225–227